Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088653 | 0.97 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1KDM4EMAPK1ATM | |
| SCHEMBL10088661 | 0.94 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1KDM4EMAPK1ATM | |
| SCHEMBL10088649 | 0.93 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1KDM4EMAPK1ATM | |
| SCHEMBL10088987 | 0.92 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL2385531 | 0.91 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1KDM4EMAPK1ATM | |
| SCHEMBL2327269 | 0.91 | S1PR1 (0.45) | L3MBTL1MAPK1 | |
| SCHEMBL10088663 | 0.90 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1KDM4EMAPK1ATM | |
| SCHEMBL10088829 | 0.90 | MAPK1 (0.45) | L3MBTL1ALDH1A1KDM4EMAPK1GAA | |
| SCHEMBL10089053 | 0.89 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1KDM4EMAPK1ATM | |
| SCHEMBL10088665 | 0.88 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1KDM4ETDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | L3MBTL1 2259/4885ALDH1A1 2201/4885KDM4E 3199/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | L3MBTL1 1453/4885ALDH1A1 2294/4885KDM4E 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.